Skip to main content
. 2011 Feb 1;121(3):1044–1052. doi: 10.1172/JCI43844

Figure 8. AAV9-SERCA2a gene therapy mitigates disease in Sgcd–/– gastrocnemius.

Figure 8

(A) Representative histological H&E stain of gastrocnemius from injected neonates taken 6 weeks later given control AAV9-GFP or experimental AAV9-SERCA2a. Original magnification, ×200. (B) Quantitation of myofiber central nucleation in the 2 groups taken from 4 mice analyzed. *P < 0.05 versus GFP.